Bright, but not as big: Solar projects could be downsized to protect wildlife
The two massive solar projects winding toward approval on San Luis Obispo County’s Carrizo Plain could end up generating 30 percent less energy than the 800 megawatts their corporate backers would prefer. That is according to draft environmental impact reports circulating for the California Valley Solar Ranch, backed by San Jose-based SunPower Corp., and the Read More →
Read More →Inphi predicts $10-$12 IPO price
Inphi Corp., the chip design firm with a big presence in Ventura County, expects the shares of its initial public offering to sell for between $10 and $12. With shares scheduled to hit the market as early as Nov. 10, Inphi would raise $74.8 million if investors buy in the middle of its range. It Read More →
Read More →Giving more than time: Tech companies lend their skills to nonprofits
When businesses think about giving back to their communities, they typically turn to giving cash or volunteering to help build houses or serve up food. But tri-county technology companies are finding they can have a big impact in just a few hours by donating their skills and expertise. In San Luis Obispo, Hathway, a Web Read More →
Read More →Amgen reports earnings drop
Thousand Oaks-based Amgen said Oct. 25 that third-quarter earnings fell 14 percent to $1.3 billion as revenue flatlined. Amgen is the world’s biggest biotech company and the largest private employer in the Tri-Counties. It reported adjusted earnings per share of $1.36, a decrease of 9 percent compared to the same quarter last year. Total revenue Read More →
Read More →UTC to buy rest of Clipper
United Technologies Corp., a multinational firm that owns nearly half of Carpinteria-based Clipper Windpower, has reached an agreement with Clipper to buy the rest of the turbine maker. UTC acquired 49.5 percent of Clipper in December in a deal that gave it the right to boost its stake to 55 percent in 2012 — or Read More →
Read More →FDA OKs Aranesp for pre-dialysis patients
Amgen’s anemia treatment Aranesp is safe for kidney patients whose disease doesn’t require dialysis, a federal panel announced Oct. 18 in response to a study that found the drug could increase stroke risk in those patients. Outside advisers to the U.S. Food and Drug Administration said the treatment shouldn’t be withdrawn or limited to a Read More →
Read More →
